UK Markets closed

  • FTSE 100

    6,695.07
    -20.35 (-0.30%)
     

  • FTSE 250

    20,596.91
    -196.81 (-0.95%)
     

  • AIM

    1,195.31
    -2.78 (-0.23%)
     

  • GBP/EUR

    1.1236
    -0.0045 (-0.40%)
     

  • GBP/USD

    1.3685
    -0.0046 (-0.3339%)
     

  • BTC-GBP

    23,313.61
    +74.85 (+0.32%)
     

  • CMC Crypto 200

    651.44
    +41.45 (+6.79%)
     

  • S&P 500

    3,841.47
    -11.60 (-0.30%)
     

  • DOW

    30,996.98
    -179.03 (-0.57%)
     

  • CRUDE OIL

    51.98
    -1.15 (-2.16%)
     

  • GOLD FUTURES

    1,855.50
    -10.40 (-0.56%)
     

  • NIKKEI 225

    28,631.45
    -125.41 (-0.44%)
     

  • HANG SENG

    29,447.85
    -479.91 (-1.60%)
     

  • DAX

    13,873.97
    -32.70 (-0.24%)
     

  • CAC 40

    5,559.57
    -31.22 (-0.56%)
     
Brexit:

UK meat traders face being locked out of Dutch market amid Brexit red tape

Importers need to ensure they have the correct veterinary health paperwork and have 90 days to sort out any issues

MorphoSys AG: Corporate Calendar 2021

·5-min read

DGAP-News: MorphoSys AG / Key word(s): Miscellaneous
17.12.2020 / 22:00
The issuer is solely responsible for the content of this announcement.

Media Release
Planegg/Munich, Germany, December 17, 2020

MorphoSys AG: Corporate Calendar 2021

 

Dear Madam/Sir,

Please note MorphoSys's financial reporting dates 2021 as follows:

 


For a direct import of the dates to your calendar, please visit our corporate website: https://www.morphosys.com/media-and-investors/morphosys-events#company-calendar

With season's greetings and best wishes for the New Year:
www.morphosys.com/xmas-2020

About MorphoSys
MorphoSys (FSE & NASDAQ: MOR) is a commercial-stage biopharmaceutical company dedicated to the discovery, development and commercialization of exceptional, innovative therapies for patients suffering from serious diseases. The focus is on cancer. Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In 2017, Tremfya(R), developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc., for the treatment of plaque psoriasis, became the first drug based on MorphoSys' antibody technology to receive regulatory approval. In July 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval of MorphoSys' proprietary product Monjuvi(R) (tafasitamab-cxix) in combination with lenalidomide in patients with a certain type of lymphoma.

Headquartered near Munich, Germany, the MorphoSys group, including the fully owned U.S. subsidiary MorphoSys US Inc., has ~500 employees. More information at www.morphosys.com or www.morphosys-us.com.

Monjuvi(R) is a registered trademark of MorphoSys AG.
Tremfya(R) is a registered trademark of Janssen Biotech, Inc.

MorphoSys forward looking statements
This communication contains certain forward-looking statements concerning the MorphoSys group of companies, including the expectations regarding Monjuvi's ability to treat patients with relapsed or refractory diffuse large B-cell lymphoma, the further clinical development of tafasitamab-cxix, including ongoing confirmatory trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "would," "could," "potential," "possible," "hope" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve known and unknown risks and uncertainties, which might cause the actual results, financial condition and liquidity, performance or achievements of MorphoSys, or industry results, to be materially different from any historic or future results, financial conditions and liquidity, performance or achievements expressed or implied by such forward-looking statements. In addition, even if MorphoSys' results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Among the factors that may result in differences are MorphoSys' expectations regarding risks and uncertainties related to the impact of the COVID-19 pandemic to MorphoSys' business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products, the global collaboration and license agreement for tafasitamab, the further clinical development of tafasitamab, including ongoing confirmatory trials, and MorphoSys' ability to obtain and maintain requisite regulatory approvals and to enroll patients in its planned clinical trials, additional interactions with regulatory authorities and expectations regarding future regulatory filings and possible additional approvals for tafasitamab-cxix as well as the commercial performance of Monjuvi, MorphoSys' reliance on collaborations with third parties, estimating the commercial potential of its development programs and other risks indicated in the risk factors included in MorphoSys' Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. MorphoSys expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements, unless specifically required by law or regulation.

For more information, please contact:
MorphoSys AG


17.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

 

Publication of Interim Statement / Report

Conference Call

Year-End Results 2020

March 15, 2021 // 10 pm CET
(5 pm EDT; 9 pm GMT)

March 16, 2021 // 2 pm CET
(9 am EDT; 1 pm GMT)

First Quarter Interim Statement 2021

May 5, 2021 // 10 pm CEST
(4 pm EDT; 9 pm BST)

May 6, 2021 // 2 pm CEST
(8 am EDT; 1 pm BST)

Half-Year Report 2021

July 28, 2021 // 10 pm CEST
(4 pm EDT; 9 pm BST)

July 29, 2021 // 2 pm CEST
(8 am EDT; 1 pm BST)

Third Quarter Interim Statement 2021

Nov. 10, 2021 // 10 pm CET
(4 pm EST; 9 pm GMT)

Nov. 11, 2021 // 2 pm CET
(8 am EST; 1 pm GMT)

 

 

 

Annual General Meeting

May 19, 2021

 

Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 89927 26079
Thomas.Biegi@morphosys.com

Myles Clouston
Senior Director
Tel: +1 857-772-0240
myles.clouston@morphosys.com

Jeanette Bressi
Director, US Communications
Tel: +1 617-404-7816
jeanette.bressi@morphosys.com

 

Publication of Interim Statement / Report

Conference Call

Year-End Results 2020

March 15, 2021 // 10 pm CET
(5 pm EDT; 9 pm GMT)

March 16, 2021 // 2 pm CET
(9 am EDT; 1 pm GMT)

First Quarter Interim Statement 2021

May 5, 2021 // 10 pm CEST
(4 pm EDT; 9 pm BST)

May 6, 2021 // 2 pm CEST
(8 am EDT; 1 pm BST)

Half-Year Report 2021

July 28, 2021 // 10 pm CEST
(4 pm EDT; 9 pm BST)

July 29, 2021 // 2 pm CEST
(8 am EDT; 1 pm BST)

Third Quarter Interim Statement 2021

Nov. 10, 2021 // 10 pm CET
(4 pm EST; 9 pm GMT)

Nov. 11, 2021 // 2 pm CET
(8 am EST; 1 pm GMT)

 

 

 

Annual General Meeting

May 19, 2021

 

Investor Contacts:
Dr. Julia Neugebauer
Senior Director
Tel: +49 (0)89 / 899 27 179
julia.neugebauer@morphosys.com

Media Contacts:
Thomas Biegi
Vice President
Tel.: +49 (0)89 / 89927 26079
Thomas.Biegi@morphosys.com

Myles Clouston
Senior Director
Tel: +1 857-772-0240
myles.clouston@morphosys.com

Jeanette Bressi
Director, US Communications
Tel: +1 617-404-7816
jeanette.bressi@morphosys.com

Language:

English

Company:

MorphoSys AG

Semmelweisstr. 7

82152 Planegg

Germany

Phone:

+49 (0)89 899 27-0

Fax:

+49 (0)89 899 27-222

E-mail:

investors@morphosys.com

Internet:

www.morphosys.com

ISIN:

DE0006632003

WKN:

663200

Indices:

MDAX, TecDAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Nasdaq

EQS News ID:

1155944


 

End of News

DGAP News Service

show this
show this

Latest stories

  • Conor McGregor vs Dustin Poirier live stream: Free links to UFC 257 fight spread online amid ‘hyper-piracy’

    Illegal streaming sites pop up across Facebook, Reddit and Twitter in build-up to fight

  • Conor McGregor vs Poirier - LIVE: UFC 257 stream, latest updates and UK start time from Fight Island

    The Notorious takes on The Diamond in a rematch on the Fight Island in Abu Dhabi

  • Person in Michigan wins Mega Millions' $1 billion jackpot, 2nd-largest total ever

    One lucky person is taking home a $1 billion Mega Millions jackpot. Early Saturday, lotto officials announced a person in Michigan won the prize, estimated at $1 billion or $739.6 million should the winner choose a lump-sum payment -- before taxes. The winning numbers were 4-26-42-50-60 with a Mega Ball number of 24.

  • Conor McGregor net worth: How much money does The Notorious make ahead of UFC 257 fight?

    The Irishman is one of the most successful athletes in combat sports history

  • McGregor vs Poirier purse: How much will stars earn for UFC 257 fight?

    Conor McGregor fights Dustin Poirier at UFC 257 in Abu Dhabi

  • Conor McGregor vs Dustin Poirier live stream: How to watch UFC 257 online and on TV

    Conor McGregor fights Dustin Poirier at UFC 257 in Abu Dhabi

  • Conor McGregor vs Poirier prediction: How will UFC 257 main event finish?

    Conor McGregor fights Dustin Poirier at UFC 257 in Abu Dhabi

  • UFC 257 undercard: Who will fight before Conor McGregor vs Poirier main event?

    Conor McGregor fights Dustin Poirier at UFC 257 in Abu Dhabi

  • What time is McGregor vs Poirier in the US? UFC 257 Fight Island undercard and main event schedule

    Conor McGregor fights Dustin Poirier at UFC 257 in Abu Dhabi

  • What time is McGregor vs Poirier in the UK? UFC 257 Fight Island undercard and main event schedule

    Conor McGregor fights Dustin Poirier at UFC 257 in Abu Dhabi

  • David Bettoni praises Real Madrid’s return to form with win over Alaves

    Three days on from the embarrassing loss to third-tier Alcoyano, Real bounced back with three points at Alaves.

  • All-Star Booker out against Nuggets with hamstring injury

    Phoenix Suns All-Star guard Devin Booker sat out Saturday night against the Denver Nuggets because of a left hamstring injury he suffered in overtime Friday night. Booker was hurt with about two minutes left in overtime when he landed awkwardly while going for a rebound. Suns coach Monty Williams said on Saturday that Booker's hamstring was sore and that his status for the coming week was uncertain.

  • Rookie Bowen Byram already making impact for Avs

    Colorado Avalanche defenseman Bowen Byram is just 19, yet he already has made an impact in two career games and will get another opportunity to grow Sunday as the Avalanche again meet the host Anaheim Ducks in Southern California. Byram delivered his first point in Friday's 3-2 overtime victory over the Ducks, assisting on a third-period goal by Mikko Rantanen on Friday, when he also took four shots in 14 minutes on the ice.

  • U.S. to reverse 'draconian' immigration policies

    President Joe Biden told the Mexican president that the U.S. plans to reverse the Trump administration's "draconian" immigration approach while working on policies addressing the causes of migration, according to the White House. In a Friday call with Mexican President Andrés Manuel López Obrador, Biden outlined his plan to create new legal pathways for immigration and improve the process for people requesting asylum. The White House release also said the two leaders agreed to work together towards reducing "irregular migration.” In a Twitter post, Lopez Obrador called the call “pleasant and respectful”. The call comes two days after Biden signed half a dozen executive orders to reverse several hardline immigration policies put in place by former President Trump, including immediately lifting a travel ban on 13 mostly Muslim-majority and African countries, and halting construction of the U.S.-Mexico border wall. Over in Sunland Park, New Mexico, construction sites of the border wall appeared abandoned after Biden signed the executive order. On Thursday Lopez Obrador praised Biden for halting construction. "If President Biden says that a wall is no longer being built, that's what he means. In four years, zero.” Biden has also made an early push for a bill that would open a path for citizenship for the roughly 11 million people living in the United States illegally, though even his allies in Congress acknowledge that may be "a Herculean task."

  • Joe Biden and Boris Johnson discuss Covid-19 recovery in phone call

    PM raises prospect of free trade deal between UK and US during first discussion

  • US America's Cup challenger: heart still beats after capsize

    American Magic’s race boat Patriot might have been battered and broken when it capsized at speed during the America’s Cup challenger series in Auckland, but skipper Terry Hutchinson says its proud heart is still beating. The United States team remains in a race against time to repair Patriot, to make it fighting fit in time to face Italy’s Luna Rossa in the semifinal of the Prada Cup series beginning Friday. Hutchinson is fully confident Patriot will be at the start line and as good as new after tireless efforts from American Magic’s shore team and help from America’s Cup defender Team New Zealand.

  • Seven Big Banks Escape With Minor Fines in Mexico Antitrust Case

    (Bloomberg) -- Mexico’s antitrust body has fined seven banks a total of $1.5 million, only 4% of potential penalties, following a four-year investigation into alleged price rigging in the peso bond market, according to a document seen by Bloomberg News.Deutsche Bank AG, Barclays Plc, Bank of America Corp., Citigroup Inc.’s local unit Citibanamex, Banco Bilbao Vizcaya Argentaria SA, Banco Santander Mexico SA and JPMorgan Chase & Co. were fined a total of 29.4 million pesos out of a potential 680 million, the document showed. Deutsche Bank and Barclays got the two biggest fines at 8.7 million pesos and 6.35 million pesos, respectively.Eleven traders, whose identities weren’t disclosed, were fined a total of 5.7 million pesos out of a possible 108.5 million pesos.A spokesperson for the antitrust commission, known as Cofece, didn’t respond to a request for comment. The agency is barred from speaking publicly about its rulings until all the parties involved have been notified.JPMorgan, Bank of America and Citigroup declined to comment. A Santander Mexico spokesperson said it would comment when the decision was made public. The other banks didn’t immediately respond to a request for comment.The fines are tiny compared to the billions of dollars Barclays and Deutsche paid back in 2015 to settle charges with U.S., U.K. and European regulators. Cofece can fine companies up to 10% of their revenues when they engage in cartel-like behavior, but the maximum fines listed in the documents were smaller and the actual fines at the bottom of the range.The commission ruled Jan. 14 and began notifying banks of fines last week.In late 2019, the commission’s investigative unit said it found evidence of collusion after a three-year probe that examined 10 years of trader chats and bank records. Cofece said in early 2017 that it was investigating banks for colluding to manipulate prices in both central bank auctions and when selling to funds and clients.People charged in the case said investigators found only isolated examples of alleged price fixing or discussions of clients orders in group chats from early last decade. There were no charges of collusion in central bank auctions, the people said.New RulesIn the wake of the price fixing probes that followed the 2008-09 global financial crisis, banks implemented tighter restrictions on chat rooms that make collusion harder.Cofece is under political pressure after Mexican President Andres Manuel Lopez Obrador said this month that lawmakers should fold the functions of the country’s autonomous regulators into his federal ministries. Local media reports had stoked expectations that the fines could be huge, and included inaccurate reports of evidence of price rigging in central bank auctions.Last year, Barclays and JPMorgan agreed to pay a combined $20.7 million to settle charges in New York that their Mexican affiliates conspired with other banks to sell Mexican bonds at inflated prices to U.S. pension funds. That case stemmed from information gathered in the Cofece probe. The U.S. judge later threw out charges against the rest of the banks, arguing he didn’t have jurisdiction over alleged manipulation in Mexico.Mexico’s securities and banking regulator did its own investigation and fined six global banks and traders in late 2018 a total of a little over $1 million for manipulating bond-trading volumes.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • Prisoners will not jump jab queue as ‘Levi Bellfield offered vaccine’

    Those aged over 70, health and social care workers and clinically extremely vulnerable people are highest in the priority list.

  • Biggs on Liz Cheney's vote to impeach Trump

    Rep. Andy Biggs reacts to Guardsmen controversy and Trump impeachment on 'Fox Report'

  • Food Network Pulls ‘Worst Cooks In America’ Season 20 After Champion Charged With Child Murder

    The Food Network has scrubbed its latest season of reality series Worst Cooks In America after its champion has been arrested for a child’s murder. Ariel Robinson, age 29, was charged Tuesday along with her husband Jerry Robinson in the death of a 3-year-old girl in South Carolina. They face counts of homicide by child abuse […]